BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/22/2022 9:25:37 AM | Browse: 779 | Download: 1906
 |
Received |
|
2021-03-18 01:39 |
|
Peer-Review Started |
|
2021-03-18 02:14 |
|
First Decision by Editorial Office Director |
|
2021-07-18 05:06 |
|
Return for Revision |
|
2021-07-18 05:06 |
|
Revised |
|
2021-08-22 15:06 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-01-24 03:56 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-01-25 03:26 |
|
Articles in Press |
|
2022-01-25 03:26 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-02-15 09:28 |
|
Publish the Manuscript Online |
|
2022-02-22 09:25 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Eduardo Fassio, Fernando J Barreyro, M Soledad Pérez, Diana Dávila, Graciela Landeira, Gisela Gualano and Gabriela Ruffillo |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Eduardo Fassio, MD, Hepatology Section, Gastroenterology Service, Hospital Nacional Prof. Alejandro Posadas, Av. Presidente Illia y Marconi, s/n, El Palomar 1684, Buenos Aires, Argentina. efassio@intramed.net |
| Key Words |
Hepatocellular carcinoma; Metabolic dysfunction-associated fatty liver disease; Nonalcoholic fatty liver disease; Surveillance for hepatocellular carcinoma; Incidence of hepatocellular carcinoma; Nonalcoholic steatohepatitis |
| Core Tip |
Metabolic dysfunction-associated fatty liver disease (MAFLD) affects 25% of general population worldwide. Within that huge number of patients, a minority will progress to cirrhosis, with an annual incidence rate of hepatocellular carcinoma (HCC) > 1%. In them, surveillance for HCC by means of ultrasound with or without alpha-fetoprotein measurement is cost-effective. In patients with MAFLD cirrhosis who are men, older and diabetic, risk is even higher and magnetic resonance imaging might be a better screening test. However, the great challenge is stratifying the HCC risk in patients with MAFLD without cirrhosis. Factors that can help to stratify their risk (genetic, demographic, metabolic, non-invasive fibrosis tests) will be reviewed. |
| Publish Date |
2022-02-22 09:25 |
| Citation |
Fassio E, Barreyro FJ, Pérez MS, Dávila D, Landeira G, Gualano G, Ruffillo G. Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations? World J Hepatol 2022; 14(2): 354-371 |
| URL |
https://www.wjgnet.com/1948-5182/full/v14/i2/354.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v14.i2.354 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
